Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine)

靶向CD30嵌合抗原受体T细胞疗法（中国人民解放军总医院/西比曼生物科技）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine)
Drug Alias NameCAR30-NKTCD30ScFv-CD8-CD137-CD3zetaCBM-C30.1
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulators
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPla General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPla General HospitalCellular Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A